Sign Up Today and Learn More About Delfi Diagnostics Stock
Invest in or calculate the value of your shares in Delfi Diagnostics or other pre-IPO companies through EquityZen's platform.
Delfi Diagnostics Stock (DELD)
Delfi Diagnostics detects cancer early, when it is most curable, using high precision non-invasive blood tests.
About Delfi Diagnostics Stock
Founded
2019
Headquarters
Baltimore, MD, US
Industries
Software, Artificial Intelligence, Data and Analytics
Delfi Diagnostics detects cancer early, when it is most curable, using high-precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. The company was founded in 2019 and is based in Baltimore, Maryland.
Delfi Diagnostics Press Mentions
Stay in the know about the latest news on Delfi Diagnostics
Earlier Detection and Treatment are Essential for Meeting VBC Goals
medcitynews • Nov 04, 2024
People in the News at 23andMe, Delfi Diagnostics, Cofactor Genomics, Proteomics International
genomeweb • Nov 03, 2024
DELFI Diagnostics Names Robert Guigley as Chief Commercial Officer to Expand Access to Early Cancer Screening
prnewswire • Oct 29, 2024
DELFI Diagnostics Appoints Thomas Russo as Chief Financial Officer
prnewswire • Aug 26, 2024
Indigenous Pact and DELFI Diagnostics Join Forces to Enhance Lung Cancer Screening in Tribal Communities
prnewswire • Aug 05, 2024
Investors in Delfi Diagnostics
Discover investors in Delfi Diagnostics stock and explore their portfolio companies
Delfi Diagnostics Management
Leadership team at Delfi Diagnostics
Board Member
Justin Kao
Board Observer
Wouter Meuleman
Join now and verify your accreditation status to gain access to:
- Delfi Diagnostics current valuation
- Delfi Diagnostics stock price
- Available deals in Delfi Diagnostics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Delfi Diagnostics stock?
Accredited investors can buy pre-IPO stock in companies like Delfi Diagnostics through EquityZen funds. These investments are made available by existing Delfi Diagnostics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Delfi Diagnostics stock?
Shareholders can sell their Delfi Diagnostics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
